While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies — as Jeff Bezos said, “Your margin is my opportunity”.

Not all profitable companies are created equal, and that’s why we built StockStory - to help you find the ones that truly shine bright. Keeping that in mind, here are three profitable companies to avoid and some better opportunities instead.

Photronics (PLAB)

Trailing 12-Month GAAP Operating Margin: 22.5%

Sporting a global footprint of facilities, Photronics (NASDAQ: PLAB) is a manufacturer of photomasks, templates used to transfer patterns onto semiconductor wafers.

Why Are We Cautious About PLAB?

1. Flat sales over the last two years suggest it must find different ways to grow during this cycle
2. Estimated sales growth of 2.2% for the next 12 months is soft and implies weaker demand
3. Gross margin of 34.7% reflects its high production costs

Photronics is trading at $28.49 per share, or 14.2x forward P/E. If you’re considering PLAB for your portfolio, see our FREE research report to learn more.

Global Industrial (GIC)

Trailing 12-Month GAAP Operating Margin: 6.6%

Formerly known as Systemax, Global Industrial (NYSE: GIC) distributes industrial and commercial products to businesses and institutions.

Why Are We Wary of GIC?

1. Sales trends were unexciting over the last two years as its 3.3% annual growth was below the typical industrials company
2. Flat earnings per share over the last two years lagged its peers
3. Shrinking returns on capital suggest that increasing competition is eating into the company’s profitability

Global Industrial’s stock price of $38.84 implies a valuation ratio of 19.4x forward P/E. To fully understand why you should be careful with GIC, check out our full research report (it’s free).

Artivion (AORT)

Trailing 12-Month GAAP Operating Margin: 4.4%

Formerly known as CryoLife until its 2022 rebranding, Artivion (NYSE: AORT) develops and manufactures medical devices and preserves human tissues used in cardiac and vascular surgical procedures for patients with aortic disease.

Why Is AORT Not Exciting?

1. Modest revenue base of $471.5 million gives it less fixed cost leverage and fewer distribution channels than larger companies
2. Cash burn makes us question whether it can achieve sustainable long-term growth
3. Low returns on capital reflect management’s struggle to allocate funds effectively

At $24.65 per share, Artivion trades at 50.8x forward P/E. Read our free research report to see why you should think twice about including AORT in your portfolio.

High-Quality Stocks for All Market Conditions

ALSO WORTH WATCHING: Top 5 Momentum Stocks. The best time to own a great stock is when the market is finally noticing it. These aren’t just high-quality businesses. Something is happening with them right now. Elite fundamentals meet near-term momentum — both boxes checked at the same time.

Find out which stocks our AI platform is flagging this week. See this week’s Strong Momentum stocks — FREE. Get Our Strong Momentum Stocks for Free HERE.

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+271% between June 2020 and June 2025). Find your next big winner with StockStory today.